白细胞三烯拮抗剂ONO－1078对豚鼠迷走神经电刺激引起气道痉挛及微血管渗漏作用

阿托品预先处理的豚鼠，电刺激迷走神经（１０Ｈｚ，５ｍｓ，２Ｖ或１０Ｖ，９０ｓ）引起气道阻力增高，气管、主支气管和肺内气道的依文思蓝渗出量增加，并随刺激强度加大而增强。白细胞三烯拮抗剂ＯＮＯ－１０７８（０．０３，０．１ｍｇ·ｋｇ－１，ｉｖ）对气道阻力的增高无明显影响；但显著抑制微血管渗漏，在刺激强度低（２Ｖ）时更明显。结果提示白细胞三烯类参与神经原性炎症时的气道微血管渗漏反应。     

药物对抗原诱导的气道阻力增高和微血管渗漏的作用

在致敏豚鼠,白三烯拮抗剂ONO-1078抑制抗原诱导的气道(支气管和肺)微血管渗漏和气道阻力增高,甲吡酮可以增强抗原诱导的两种反应,氢化可的松可抑制抗原的反应和甲吡酮的增强作用。在上述反应中,气道的微血管渗漏和气道阻力增高之间有显著的相关关系。结果说明这些药物对气道的作用,与改变气道阻力和微血管渗漏性都有关。     

白三烯拮抗剂ONO-1078对化学物质诱导大鼠皮肤微血管渗漏的抑制作用

大鼠皮内注射组胺、辣椒素和甲醛诱导皮肤微血管渗漏,白三烯拮抗剂ONO-1078剂量依赖性抑制这一反应,ID₅₀分别为1.98,1.78,2.23mg·kg^-1。与扑尔敏相比,对组胺的作用较弱,对辣椒素和甲醛的作用较强,地塞米松的作用强于ONOl078和扑尔敏。ONO-l078还抑制LTD4的作用,对大剂量组胺、缓激肽和P物质无明显作用。ONO-l078的作用可能与抑制感觉神经肽释放有关。     

药物对抗原诱导的气道阻力增高和微血管渗漏的作用

在致敏豚鼠，白三烯拮抗剂ＯＮＯ－１０７８抑制抗原诱导的气道（支气管和肺）微血管渗漏和气道阻力增高，甲吡酮可以增强抗原诱导的两种反应，氢化可的松可抑制抗原的反应和甲吡酮的增强作用。在上述反应中，气道的微血管渗漏和气道阻力增高之间有显著的相关关系。结果说明这些药物对气道的作用，与改变气道阻力和微血管渗漏性都有关。     

速激肽受体拮抗剂对白三烯C4引起的豚鼠心血管反应的抑制作用

iv白三烯C₄(LTC₄)0.8nmol·kg^-1引起麻醉豚鼠血压降低和心脏微血管依文思蓝渗出增加。速激肽NK-1受体拮抗剂CP-96345 (2.06μmol·kg^-1,iv)和NK-2受体拮抗剂SR-48968(1.66μmol·kg^-1,iv)部分抑制心房微血管渗漏(分别为46.6%和37.5%);两药合用可明显抑制LTC₄引起的低血压和心房、心室微血管渗漏(分别为58.1%和54.1%),其作用与白三烯特异性拮抗剂ONO-1078(0.06μmol·kg^-1,iv)相似。结果表明速激肽NK-1和NK-2受体可能参与白三烯引起的低血压和心脏炎症反应。     

小剂量哌替啶对香烟烟雾致豚鼠急性肺气道反应的影响

目的研究小剂量阿片受体激动剂哌替啶(Peth)对香烟烟雾吸入引起的豚鼠急性气道收缩反应和炎性反应的影响。方法观察Peth0.01,0.1和1mg.kg-1对豚鼠自主吸入75%香烟烟雾(含25%O2)60mL后,气道阻力和肺动态顺应性变化的影响及气道组织血管通透性变化的影响;观察Peth0.1mg.kg-1对豚鼠2h内分6次吸入(共360mL)75%浓度的香烟烟雾后,支气管肺泡灌洗液(BALF)中白细胞总数和分类计数改变的影响,测定BALF中一氧化氮(NO)含量。结果Peth能减轻或明显抑制香烟烟雾刺激后气道阻力增高和肺动态顺应性下降的反应,抑制气道组织各段微血管通透性增加的反应,降低BALF中的白细胞总数和中性粒细胞比例,降低BALF中NO的含量。结论小剂量Peth对豚鼠急性神经源性气道收缩反应和炎性反应具有抑制作用。     

羊红膻根中羊红膻素A及羊红膻素B的分离和鉴定

从草药羊红膻(Pimpinela thelungiana Wolf)根中分得2个化合物,经光谱解析(UV,IR,MS,¹HNMR,¹H ¹HCOSY,¹³CNMR,¹³C-¹HCOSY和DEPT),鉴定为2-(1-ethoxy-2-hydroxy)propyl-4-methoxyphenol(I)和2-(1-ethoxy-2-hydroxy)propyl-4-methoxyphenyl-2-methyl-butyrate(II),分别命名为羊红膻素A及羊红膻素B,为2个新的天然产物,药理实验表明这2个新化合物均有较明显的降压活性。     

前列腺癌显像剂~(18)F-8-乙氧基-2-(4-氟苯基)-3-硝基-2H-色烯的合成

目的制备前列腺癌显像剂~(18)F-8-乙氧基-2-(4-氟苯基)-3-硝基-2H-色烯的前体8-乙氧基-2-(4-N,N,N-三甲基氨基苯基)-3-硝基-2H-色烯季胺三氟甲磺酸盐;用前体和放射性核素~(18)F合成~(18)F-8-乙氧基-2-(4-氟苯基)-3-硝基-2H-色烯。方法以2-羟基-1-乙氧基-3-醛基苯为起始原料,经烯化、环化、磺化、成盐反应得到标记前体8-乙氧基-2-(4-N,N,N-三甲基氨基苯基)-3-硝基-2H-色烯季胺三氟甲磺酸盐;然后与放射性核素~(18)F经亲核氟代反应,得到~(18)F-8-乙氧基-2-(4-氟苯基)-3-硝基-2H-色烯。标记前体8-乙氧基-2-(4-N,N,N-三甲基氨基苯基)-3-硝基-2H-色烯季胺三氟甲磺酸盐及各步反应中间体的结构均经核磁共振谱和质谱确证。结果与结论成功合成前列腺癌诊断显影剂~(18)F-8-乙氧基-2-(4-氟苯基)-3-硝基-2H-色烯,标记率为(25.8±2.6)%(n=5,未经衰减校正),TLC测定其放化纯度(RCP)为97.5%,为进一步临床研究奠定了基础。     

白三烯拮抗剂ONO-1078对电刺激迷走神经、辣椒素和P物质引起的豚鼠心血管反应的作用(英文)

阐明ONO-1078(ONO,4-氧-8-[对-(4-苯丁氧基)苯甲酰氨基]-2-(5-四唑基)-4H-1-苯并毗喃)对神经原性刺激诱导心血管反应的作用.方法:观察豚鼠心房和心室伊文思蓝渗出以及平均主动脉压(MAP)变化.结果:在阿托品(1 mg·kg~(-1),iv)预先处理后,电刺激迷走神经(ESV,10 Hz,5 ms,2或10 V,90 s)显著增高伊文思蓝渗出;辣椒素和P物质也增加染料渗出并降低平均动脉压(MAP).ONO(0.03,0.1 mg·kg~(-1),iv)抑制ESV的反应,在刺激强度低(2 V)时更明显;ONO 0.03 mg·kg~(-1)减弱辣椒素引起的微血管渗漏和低血压,但对P物质无影响.结论:ONO-1078可能通过抑制感觉神经肽释放而调节神经原性炎症时的心血管反应.     

新化合物 A-失碳-17β-羟基-17α-乙炔基-Δ3(5),9(10)-雌甾二烯-2-酮的合成

报道新化合物A-失碳-17β-羟基-17α-乙炔基-Δ^3(5),9(10)-雌甾二烯-2-酮2的合成。文中探讨了用炔钾粗品对A-失碳-Δ^3(5),9(10)-雌甾二烯-2，17-二酮１和Ａ-失碳-６β，１９-环氧-Δ³-雄甾-2，17-二酮3的选择性炔化，分别得标题化合物2（44%）及Ａ-失碳-17β-羟基-17α-乙炔基-６β，１９-环氧-Δ³雄甾-2-酮４（６５％），４经还原性破开环氧、去羟甲基和去醋酰氧基合成了标题化合物２。四步总收率为３４％。     

速激肽受体拮抗剂对白三烯C_4诱导豚鼠气道收缩和微血管渗漏的作用

本实验探讨了内源性速激肽是否参与白三烯Ｃ４（ＬＴＣ４）的气道效应．ＬＴＣ４（０．５μｇｋｇ－１，ｉｖ）可增高豚鼠肺内压（ＩＰＰ）和气道内依文思蓝渗出。速激肽ＮＫ－１受体拮抗剂ＣＰ－９６３４５｛（２Ｓ，３Ｓ）－顺式－２－（二苯甲基）－Ｎ－［（２－甲氧苯）－甲基］－１－杂氮双环［２．２．２］辛烷－３－胺｝１ｍｇｋｇ－１，ｉｖ，可减弱ＬＴＣ４诱导的依文思蓝渗出；ＮＫ－２受体拮抗剂ＳＲ－４８９６８｛（Ｓ）－Ｎ－甲基－Ｎ－［４－（４－乙酰氨基－４－苯基哌啶）－２－（３，４－二氯苯基）丁基］苯甲酰胺｝，１ｍｇｋｇ－１，ｉｖ，可抑制ＩＰＰ的增高．白三烯拮抗剂ＯＮＯ－１０７８（０．０３ｍｇｋｇ－１，ｉｖ）可阻断这两种反应．结果说明内源性速激肽增强ＬＴＣ４的气道作用，其中ＮＫ－１受体介导微血管渗漏，ＮＫ－２受体介导支气管收缩．     

速激肽受体拮抗剂对白三烯C4诱导豚鼠气道收缩和微血管渗漏的作用

本实验探讨了内源性速激肽是否参与白三烯C₄(LTC₄)的气道效应. LTC₄(0.5 μg·kg^-1, iv)可增高豚鼠肺内压(IPP)和气道内依文思蓝渗出。速激肽NK-1受体拮抗剂CP-96345｛(2S, 3S)-顺式-2-( 二苯甲基)-N-［(2-甲氧苯)-甲基］-1-杂氮双环［2.2.2］辛烷-3-胺｝ 1 mg·kg^-1，iv，可减弱LTC₄诱导的依文思蓝渗出；NK-2受体拮抗剂SR-48968｛(S)-N-甲基-N-［4-(4-乙酰氨基-4-苯基哌啶)-2-(3,4-二氯苯基)丁基］苯甲酰胺｝，1 mg·kg^-1， iv，可抑制IPP的增高. 白三烯拮抗剂ONO-1078 (0.03 mg·kg^-1, iv)可阻断这两种反应. 结果说明内源性速激肽增强 LTC₄的气道作用，其中NK-1受体介导微血管渗漏，NK-2受体介导支气管收缩.     

4－氧－8－［对－（4－苯丁氧基）苯甲酰氨基］－2－（5－四唑基）－4H－1－苯并吡喃抑制抗原诱导的豚鼠气道收缩及微血管渗漏的作用

在扑尔敏预先处理的致敏豚鼠，白三烯拮抗剂４－氧－８－［对－（４－苯丁氧基）苯甲酰氨基］－２－（５－四唑基）－４Ｈ－１－苯并吡喃（ＯＮＯ－１０７８，０．０３，０．３ｍｇ·ｋｇ－１，ｉｖ）显著抑制抗原引起的肺内压增高，并完全抑制肺内气道中心部和外周部的依文思蓝渗出。肺内压与这两部位的染料渗出量呈正相关，但与气管和主支气管的染料渗出无相关性。在扑尔敏处理的肺条和气管条，ＯＮＯ－１０７８（１μｍｏｌ·Ｌ－１）仅部分抑制抗原诱导的收缩（４５．８％和３３．３％）。结果说明ＯＮＯ－１０７８抑制抗原诱导的气道收缩作用，至少部分通过抑制微血管渗漏，并主要作用在相对外周的气道。     

Bradykinin-induced airflow obstruction and airway plasma exudation: effects of drugs that inhibit acetylcholine, thromboxane A2 or leukotrienes.

1. The mechanisms behind bradykinin-induced effects in the airways are considered to be largely indirect. The role of cholinergic nerves and eicosanoids, and their relationship in these mechanisms were investigated in guinea-pigs. 2. The role of cholinergic nerves was studied in animals given atropine (1 mg kg-1, i.v.), hexamethonium (2 mg kg-1, i.v.), or vagotomized. To study the role of eicosanoids, animals were pretreated with a thromboxane A2 (TxA2) receptor antagonist (ICI 192,605; 10(-6) mol kg-1, i.v.) or with a leukotriene (LT) receptor C4/D4/E4 antagonist (ICI 198,615; 10(-6) mol kg-1, i.v.). 3. After pretreatment with a drug, bradykinin (150 nmol) was instilled into the tracheal lumen. We measured both airway insufflation pressure (Pi), to assess airway narrowing, and the content of Evans blue dye in airway tissue, to assess plasma exudation. 4. Bradykinin instillation into the trachea caused an increase in Pi and extravasation of Evans blue dye. The increase in Pi was significantly attenuated by atropine or the TxA2 receptor antagonist, but not by hexamethonium, vagotomy or the LT receptor antagonist. 5. The bradykinin-induced exudation of Evans blue dye was significantly attenuated in the intrapulmonary airways by the TxA2 receptor antagonist, but not by atropine, hexamethonium, cervical vagotomy or the LT receptor antagonist. 6. A thromboxane-mimetic U-46619 (20 nmol kg-1, i.v. or 10 nmol intratracheally), caused both an increase in Pi and extravasation of Evans blue dye at all airway levels. Atropine pretreatment slightly attenuated the peak Pi after the intratracheal administration of U-46619, but not after i.v. administration.(ABSTRACT TRUNCATED AT 250 WORDS)     

Differential effects of phosphoramidon on neurokinin A- and substance P-induced airflow obstruction and airway microvascular leakage in guinea-pig.

1. The effects of the inhaled neuropeptides, neurokinin A (NKA) and substance P (SP) on lung resistance (RL) and airway microvascular permeability were studied in anaesthetized guinea-pigs. 2. Single doses of inhaled NKA (3 x 10(-5), 1 x 10(-4), 3 x 10(-4) M; 45 breaths) and SP (1 x 10(-4), 3 x 10(-4), 1 x 10(-3); 45 breaths) caused a dose-dependent increase in both RL and airway microvascular leakage, assessed as extravasation of the albumin marker, Evans blue dye. 3. NKA at 1 x 10(-4) and 3 x 10(-4) M resulted in a significantly higher increase in RL than SP at the same doses. 4. Inhaled SP (3 x 10(-4) M; 45 breaths) caused significantly higher Evans blue dye extravasation in main bronchi and proximal intrapulmonary airways compared to the same dose of NKA. 5. Pretreatment with the specific inhibitor of neural endopeptidase (NEP24.11), phosphoramidon, caused an approximately 100 fold leftward shift of the RL responses to inhaled NKA and SP. 6. Phosphoramidon significantly potentiated both NKA- and SP-induced airway microvascular leakage at proximal intrapulmonary airways, but not at any other airway level. 7. Inhibition of NEP24.11 potentiate both the SP- or NKA-induced airflow obstruction to a larger extent than the induced airway microvascular leakage, suggesting that NEP24.11 is more important in the modulation of the airflow obstruction observed after these mediators.     

Increase in vascular permeability produced in rat airways by PAF: potentiation by adrenalectomy.

1. The effect of bilateral adrenalectomy on the sensitivity of blood vessels in rat airways to mediators that increase vascular permeability was examined. 2. An increase in vascular permeability was induced by intravenous platelet activating factor (PAF, 50, 100, 500, 1000 ng kg-1) and measured by quantifying the extravasation of Evans blue dye. 3. PAF consistently increased the amount of Evans blue extravasation in the larynx, trachea, main bronchi and intrapulmonary airways in sham-operated rats. 4. The magnitude of this extravasation was significantly greater in the larynx (P less than 0.05), trachea (P less than 0.05) and main bronchi (P less than 0.05) of the adrenalectomized rats than it was in these tissues of the sham-operated rats. 5. When adrenalectomized rats were given subcutaneous dexamethasone (0.2 mg kg-1 4 h before PAF) the amount of plasma extravasation produced by PAF was decreased to the level of the sham-operated rats. 6. We conclude that adrenalectomy potentiates the increase in airway vascular permeability induced by PAF in rats and that this effect may be due to the depletion of endogenous corticosteroids.     

Bradykinin-induced plasma exudation in guinea-pig airways: involvement of platelet activating factor.

1. We studied the effect of bradykinin on plasma exudation in the airways of the anaesthetized guinea-pig in vivo. Tissue content of extravasated Evans blue dye was used as an index of protein exudation in the larynx, trachea, main bronchi and intrapulmonary airways (i.p.a.). 2. Bradykinin increased the content of Evans blue in all tissues studied in a dose-related manner. The response was greatest in the main bronchi and i.p.a., less in the trachea and least in the larynx. A dose of 47 nmol kg-1 was the lowest tested which caused significant (P less than 0.001) plasma exudation with increases in leakage above control values of 256% in the larynx, 405% in the trachea, 394% in the main bronchi and 485% in intrapulmonary airways. 3. Leakage was significantly (P less than 0.05) increased above control values by 1 min after bradykinin (47 nmol kg-1) in the main bronchi and intrapulmonary airways and was maximal in all airways 5 min after bradykinin. Although reduced by 15 min, the tissue content of dye was still significantly (P less than 0.05) increased 2 h after bradykinin. 4. The prolonged tissue dye retention was due to a later phase of slow and maintained exudation preventing full clearance of dye after the initial response. 5. The initial phase of leakage was partially attenuated by the platelet activating factor (PAF) receptor antagonists WEB 2086 or BN 52021, by indomethacin or by inhibiting sensory nerve activation by opioid anaesthesia: it was not affected by mepyramine and cimetidine nor by the sulphidopeptide leukotriene receptor antagonists FPL 55712 or ICI 198,615.(ABSTRACT TRUNCATED AT 250 WORDS)     

Neurogenic plasma leakage in mouse airways

1. This study sought to determine whether neurogenic inflammation occurs in the airways by examining the effects of capsaicin or substance P on microvascular plasma leakage in the trachea and lungs of male pathogen-free C57BL/6 mice. 2. Single bolus intravenous injections of capsaicin (0.5 and 1 micromol kg(-1), i.v.) or substance P (1, 10 and 37 nmol kg(-10, i.v.) failed to induce significant leakage in the trachea, assessed as extravasation of Evans blue dye, but did induce leakage in the urinary bladder and skin. 3. Pretreatment with captopril (2.5 mg kg(-1), i.v.), a selective inhibitor of angiotensin converting enzyme (ACE), either alone or in combination with phosphoramidon (2.5 mg kg(-1), i.v.), a selective inhibitor of neutral endopeptidase (NEP), increased baseline leakage of Evans blue in the absence of any exogenous inflammatory mediator. The increase was reversed by the bradykinin B2 receptor antagonist Hoe 140 (0.1 mg kg(-1), i.v.). 4. After pretreatment with phosphoramidon and captopril, capsaicin increased the Evans blue leakage above the baseline in the trachea, but not in the lung. This increase was reversed by the tachykinin (NK1) receptor antagonist SR 140333 (0.7 mg kg(-1), i.v.), but not by the NK2 receptor antagonist SR 48968 (1 mg kg(-1), i.v.). 5. Experiments using Monastral blue pigment as a tracer localized the leakage to postcapillary venules in the trachea and intrapulmonary bronchi, although the labelled vessels were less numerous in mice than in comparably treated rats. Blood vessels of the pulmonary circulation were not labelled. 6. We conclude that neurogenic inflammation can occur in airways of pathogen-free mice, but only after the inhibition of enzymes that normally degrade inflammatory peptides. Neurogenic inflammation does not involve the pulmonary microvasculature.